bms-986419
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 5, 2023 (NCT05847439)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
inhibitor - eIF2B
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06846866 | Phase 1 | Feb 27, 2025 | Bristol-Myers Squibb |
| NCT05963932 | Phase 1 | Aug 8, 2023 | Bristol-Myers Squibb |
| NCT05932277 | Phase 1 | Jun 29, 2023 | Bristol-Myers Squibb |
| NCT05847439 | Phase 1 | May 5, 2023 | Bristol-Myers Squibb |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 4 | 4 | 1 | 2023 |
1 organizations
Page 1 / 1